Only in hospitalized patients, in whom reduction of acid secretion of gastric juice is indicated, and it is impossible to use the preparation in oral form, eg duodenal ulcer and stomach, other syndromes with symptomatic hypersecretion of hydrochloric acid.
Composition:
1 vial of 100 ml contains 50 mg of Ranitidine as hydrochloride.
Action:
A specific, fast-acting histamine H receptor antagonist2. It inhibits both basic and postprandial secretion of hydrochloric acid and reduces the secretion of pepsin in gastric juice. The effect of a single 50 mg dose is maintained for 6-8 h. In about 15%, it binds to plasma proteins. T0,5 It is about 2.5-3 h. It is excreted by the kidneys, mainly in unchanged form (about 70%).
Contraindications:
Hypersensitivity to ranitidine or other ingredients of the preparation.
Precautions:
In patients prone to arrhythmia, the recommended infusion rate should not be exceeded. Avoid use in patients with a history of acute porphyria. The safety and efficacy of parenteral use in children have not been established. In patients treated with ranitidine in an intravenous form at a dose above 400 mg daily for more than 5 days, an increase in liver enzymes was observed.
Pregnancy and lactation:
The product should be used during pregnancy only when it is absolutely necessary, and during breastfeeding only if clearly necessary.
Side effects:
Rarely: hypersensitivity reactions (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, chest pain), transient and reversible changes in liver enzymes, skin rash. Very rare: leukopenia, thrombocytopenia (usually transient), agranulocytosis or pancytopenia with aplasia or hypoplasia of the bone marrow, anaphylactic shock, reversible confusion, depression and hallucinations (especially in severely ill and elderly patients), headaches (sometimes acute), dizziness, reversible disorders related to involuntary movements, reversible blurred vision, bradycardia, atrioventricular block, vasculitis, acute pancreatitis, diarrhea, hepatitis with or without jaundice (usually transient), erythema multiforme, hair loss, joint and muscle pain, transient impotence, gynecomastia.
Dosage:
Intravenously. 50 mg in a drip infusion lasting 15-20 min (at a rate of 5-7 ml / min). If necessary, the infusion can be repeated every 6-8 h. The preparation can also be given as a continuous infusion at a rate of 6.25 mg / h. The product does not require thinning. The daily dose may not exceed 400 mg. In patients with renal insufficiency (creatinine clearance less than 50 ml / min), it is recommended to reduce the dose by half or administer 50 mg every 18-24 h, if necessary, every 12 hours or more.
(C)
